Overview

Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis

Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Subjects will undergo peripheral blood stem cell mobilisation and collection with subsequent high-dose chemotherapy. After finalization of high-dose chemotherapy subjects will receive bone marrow derived allogeneic multipotent mesenchymal stromal cells intravenous infusion two hours prior to autologous peripheral blood cells infusion. This is a single arm study with no control. All patients receive cell therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Burnasyan Federal Medical Biophysical Center